Effect of Astragalus injection on the red blood cell, reticulocyte and platelet parameters in patients with primary nephrotic syndrome

• Main Authors: Lei Zhang, Fu-Sheng Xu, Liang Qiao, Guang-Wen Xie, Peng Lu, Shang Gao
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-01-01
• Series: Journal of Hainan Medical University
• Subjects: Primary nephrotic syndrome; Astragalus injection; Red blood cell; Reticulocyte; Platelet parameter
• Online Access: http://www.hnykdxxb.com/PDF/201602/16.pdf

Objective: To study the effect of Astragalus injection on the red blood cell, reticulocyte and platelet parameters in patients with primary nephrotic syndrome. Methods: A total of 88 patients were selected and randomly divided into two groups. Patients in the control group were treated with prednisone. Patients in the observation group were treated with Astragalus injection on the basis of prednisone treatment. Fourteen days referred to a course of treatment. After two courses of treatments, the changes of indexes and clinical therapeutic effect of red blood cells (hematocrit, erythrocyte aggregation index), reticulocyte (Retic), reticulocyte percentage (Retic%), reticulocyte hemoglobin content (CHr), thrombocytocrit (PCT), platelet volume distribution width (PDW), mean platelet volume (MPV), platelet parameters (PLT) of the two groups were observed. Results: Two groups showed statistical difference after comparison towards clinical total effective rate. They showed obvious decreased trend in hematocrit and erythrocyte aggregation index after treatment. Comparing with those of the control group, the reticulocyte percentage, reticulocyte and reticulocyte hemoglobin content also significantly decreased and showed statistically significant. The comparison of PLT, MPV, PDW, PCT between two groups showed significant differences. Conclusions: Astragalus injection can improve the blood viscosity state and related clinical symptoms by reducing the red blood cell, reticulocyte and platelet parameters in the treatment of primary nephrotic syndrome.